Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.

doi:10.1158/1078-0432.CCR-16-2592

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2017

Fujii Takeo, Barzi Afsaneh, Sartore-Bianchi Andrea, Cassingena Andrea, Siravegna Giulia, Karp Daniel D, Piha-Paul Sarina A, Subbiah Vivek, Tsimberidou Apostolia M, Huang Helen J, Veronese Silvio, Di Nicolantonio Federica, Pingle Sandeep, Vibat Cecile Rose T, Hancock Saege, Berz David, Melnikova Vladislava O, Erlander Mark G, Luthra Rajyalakshmi, Kopetz E Scott, Meric-Bernstam Funda, Siena Salvatore, Lenz Heinz-Josef, Bardelli Alberto, Janku Filip

Abstract excerpt

Purpose: Tumor-derived cell-free DNA (cfDNA) from urine of patients with cancer offers noninvasive biological material for detection of cancer-related molecular abnormalities such as mutations in Exon 2 of KRASExperimental Design: A quantitative, mutation-enrichment next-generation sequencing test for detecting KRASG12/G13 mutations in urine cfDNA was developed, and results were compared with clinical testing of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Biomarkers, Tumor

Share to Cell-Free Nucleic Acids

Share to KRAS gene

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 28096270
DOI: 10.1158/1078-0432.CCR-16-2592
PMCID: PMC5511562

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.PMID 28096270Read ↗

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.Semantic proximity Read ↗

KRAS Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and KRAS G12/G13 Detection in Cell-Free DNA.Semantic proximity Read ↗

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practiceSemantic proximity Read ↗

Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencingSemantic proximity Read ↗

Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.Semantic proximity Read ↗

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.Semantic proximity Read ↗

TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.Semantic proximity Read ↗

Asymmetric mutant-enriched polymerase chain reaction and quantitative DNA melting analysis of KRAS mutation in colorectal cancer.Semantic proximity Read ↗

Detection of CTNNB1 Hotspot Mutations in Cell-Free DNA from the Urine of Hepatocellular Carcinoma PatientsSemantic proximity Read ↗

Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.